Opinion|Videos|May 14, 2024
Non-Statin Therapies: Cost Effectiveness and Clinical Evidence Gaps
The expert panel discusses the cost-effectiveness and clinical evidence gaps for non-statin therapies, including PCSK9 inhibitors, inclisiran, and bempedoic acid.
Advertisement
Episodes in this series
Advertisement
Related to this article
The approval is supported by findings from the phase 3 OCEANIC-STROKE trial.
Pharmacy Times previews enlicitide, survodutide, diet and heart failure risk, and pharmacist-led HF care ahead of the AHA Scientific Sessions in Chicago.
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Requires Class-Wide GLP-1 RA Labeling Changes for Potential NAION Risk
2
Oral PCSK9 Inhibitor Enlicitide Sustains LDL-C Reductions
3
Survodutide Shows Cardiovascular Safety in SYNCHRONIZE-CVOT
4
How Pharmacists Help Patients Spot Patterns in Glucose Readings
5